<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">OLMESARTAN MEDOXOMIL</span><br/>(ol-me-sar'tan)<br/><span class="topboxtradename">Benicar<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">angiotensin ii receptor antagonist</span><br/><b>Prototype: </b>Losartan<br/><b>Pregnancy Category: </b>C (first trimester); D (second &amp; third trimesters)<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 20 mg, 40 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Angiotensin II receptor (type AT1) antagonist acts as a potent vasodilator and primary vasoactive hormone of the renin-angiotensin-aldosterone
         system.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Selectively blocks the binding of angiotensin II to the AT1 receptors found in many tissues (e.g., vascular smooth muscle,
         adrenal glands). Antihypertensive effect results from blocking the vasoconstricting and aldosterone-secreting effects of angiotensin
         II.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of hypertension.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to pimecrolimus or components in the cream; Netherton's Syndrome; application to active cutaneous viral infection.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Infection at topical treatment site; history of untoward effects with topical cyclosporine or tacrolimus; skin papillomas;
         immunocompromised patients.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 20 mg q.d., may increase to 40 mg q.d. Start with 510 mg q.d. if volume depleted<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Determine if patient is volume depleted (e.g., patients treated with diuretics) prior to first administration of drug. If
            volume depletion is suspected, a lower starting dose is recommended.
         </li>
<li>Store at 20°25° C (68°77° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Back pain, flu-like symptoms. <span class="typehead">CNS:</span> Headache. <span class="typehead">CV:</span> Hypotension (especially if dehydrated). <span class="typehead">GI:</span> Diarrhea. <span class="typehead">Metabolic:</span> Increased CPK, hyperglycemia, hypertriglyceridemia. <span class="typehead">Respiratory:</span> Bronchitis, pharyngitis, rhinitis, sinusitis, upper respiratory infection. <span class="typehead">Urogenital:</span> Hematuria. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase hypotensive effect of other <span class="classification">antihypertensives</span>; may cause hyperkalemia with <span class="classification">potassium-sparing diuretics</span>, <span class="classification">potassium supplements</span>; increase risk of <b>lithium</b> toxicity. <span class="typehead">Herbal:</span> Ephedra, Ma-Huang may antagonize antihypertensive effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed, 26% reaches systemic circulation. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Distribution:</span> 99% protein bound. <span class="typehead">Metabolism:</span> Not metabolized by CYP 450 system. <span class="typehead">Elimination:</span> 50% excreted in urine, 50% excreted in feces. <span class="typehead">Half-Life:</span> 13 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor closely any volume-depleted patient following initial drug doses. If serious hypotension occurs, place patient in
            supine position and notify physician immediately.
         </li>
<li>Monitor BP and HR at drug trough (prior to a scheduled dose). Report hypotension or bradycardia.</li>
<li>Monitor drug effectiveness, especially in African-Americans, when olmesartan is used as monotherapy.</li>
<li>Lab tests: Monitor baseline and periodic renal functions; monitor CBC, electrolytes, and liver function with long-term therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Discontinue drug and notify physician if you experience swelling of the face, tongue, or throat, or if you believe you are
            pregnant.
         </li>
<li>Notify physician of symptoms of hypotension (e.g., dizziness, fainting).</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>